Synmosa Biopharma Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	1,649	1,891	1,186	918.56	1,088	868.17
Short-Term Investments	263.27	318.15	120.31	520	310	115
Trading Asset Securities	793.75	721.96	575.94	211.45	20.1	5.26
Cash & Short-Term Investments	2,706	2,931	1,882	1,650	1,418	988.43
Cash Growth	-13.63%	55.73%	14.08%	16.38%	43.43%	32.61%
Accounts Receivable	1,348	1,382	1,252	1,155	1,125	799.64
Other Receivables	73.19	62.32	57.88	48.43	20.86	10.47
Receivables	1,421	1,444	1,310	1,203	1,146	810.11
Inventory	2,272	2,247	1,787	1,651	1,384	1,214
Prepaid Expenses	43.3	43.82	34.54	28.1	-	51.11
Other Current Assets	19.46	1.87	5.31	7	60.84	35.05
Total Current Assets	6,462	6,669	5,019	4,539	4,008	3,099
Property, Plant & Equipment	5,390	5,425	5,589	5,557	5,638	5,662
Long-Term Investments	450.1	387.28	336.48	222.87	223.01	303.48
Goodwill	50.26	50.26	62.29	62.29	71.08	7.27
Other Intangible Assets	374.3	383.9	449.22	496.56	496.8	494.03
Long-Term Deferred Tax Assets	409	399.47	363.27	330.56	331.78	329.28
Other Long-Term Assets	904.71	671.08	484.54	519.9	433.53	421.53
Total Assets	14,040	13,985	12,304	11,729	11,203	10,317
Accounts Payable	555.03	561.2	471.02	427.54	446.16	249.58
Accrued Expenses	465.24	496.44	443.36	381.68	368.47	264.64
Short-Term Debt	776.5	686.48	674.89	661.22	584.08	763.77
Current Portion of Long-Term Debt	317.15	230.4	72.33	289.39	584.42	413.9
Current Portion of Leases	25.1	25.57	22.94	23.3	16.7	6.74
Current Income Taxes Payable	186.16	119.75	142.57	118.29	95.54	53.18
Current Unearned Revenue	107.12	86.41	163.72	172.29	173.43	126.87
Other Current Liabilities	52.52	56.06	83.76	44.71	53.91	10.21
Total Current Liabilities	2,485	2,262	2,075	2,118	2,323	1,889
Long-Term Debt	1,401	1,537	1,729	1,400	2,122	2,272
Long-Term Leases	27.77	33.67	49.86	58.66	48.42	6.76
Long-Term Unearned Revenue	8.84	8.84	5.53	2.35	-	-
Pension & Post-Retirement Benefits	7.42	7.48	7.8	12.24	13.89	19.18
Long-Term Deferred Tax Liabilities	36.37	35.59	37.42	35.45	34.52	34.2
Other Long-Term Liabilities	1.06	1.06	1.26	0.53	12.62	0.89
Total Liabilities	3,967	3,886	3,905	3,628	4,554	4,221
Common Stock	5,102	5,102	4,293	4,014	3,437	3,131
Additional Paid-In Capital	2,623	2,627	2,082	2,195	1,425	1,426
Retained Earnings	1,413	1,279	1,096	1,092	1,005	613.43
Treasury Stock	-251.91	-154.04	-205.68	-486.96	-486.96	-402.62
Comprehensive Income & Other	-82.66	-89.1	-55.82	-104.78	-68.18	-63.04
Total Common Equity	8,803	8,764	7,210	6,710	5,312	4,706
Minority Interest	1,269	1,335	1,189	1,391	1,337	1,390
Shareholders' Equity	10,072	10,099	8,399	8,101	6,649	6,095
Total Liabilities & Equity	14,040	13,985	12,304	11,729	11,203	10,317
Total Debt	2,548	2,513	2,549	2,433	3,355	3,463
Net Cash (Debt)	158.73	418.19	-666.47	-782.59	-1,937	-2,474
Net Cash Per Share	0.32	0.84	-1.44	-1.75	-4.49	-5.69
Filing Date Shares Outstanding	499.77	502.77	462.21	462.21	429.15	432.91
Total Common Shares Outstanding	499.77	502.77	462.21	462.21	429.15	432.91
Working Capital	3,977	4,406	2,945	2,421	1,686	1,210
Book Value Per Share	17.61	17.43	15.60	14.52	12.38	10.87
Tangible Book Value	8,379	8,330	6,699	6,151	4,744	4,204
Tangible Book Value Per Share	16.77	16.57	14.49	13.31	11.05	9.71
Land	3,392	3,392	3,528	3,528	3,558	3,558
Buildings	1,620	1,619	1,587	1,567	1,558	1,542
Machinery	2,300	2,282	2,050	1,893	1,790	1,696
Construction In Progress	30.58	19.41	89.55	19.08	9.74	62.51
Leasehold Improvements	83.11	83.23	83.19	80.49	78.96	22.62